|
|
News Breaks | | | | December 28, 2012 | | 12:43 EDT |  | EBS | Emergent BioSolutions secures U.S. commercial rights to influenza vaccine
Emergent BioSolutions announced that it has signed a license agreement with VaxInnate Corporation under which Emergent acquired the exclusive right to manufacture and sell VaxInnate's pandemic influenza vaccine candidate in the United States. The product candidate, a recombinant vaccine, has the potential to be produced quickly, at high yields and in a cost-effective manner. This license enables Emergent to fulfill the requirement to secure a pandemic influenza vaccine candidate under its contract with the Biomedical Advanced Research and Development Authority. | |
|
News For EBS From The Last 14 Days Check below for free stories on EBS the last two weeks. |
|
|
| May 24, 2013 | | 13:16 EDT |  | EBS | Emergent BioSolutions management to meet with JPMorgan
 Subscribe for More Information | |
|
|
|
|
|
|
